301 related articles for article (PubMed ID: 34057732)
1. DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.
Lozinski M; Bowden NA; Graves MC; Fay M; Tooney PA
Cell Oncol (Dordr); 2021 Oct; 44(5):961-981. PubMed ID: 34057732
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
3. Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
Sorribes IC; Handelman SK; Jain HV
J R Soc Interface; 2020 Jan; 17(162):20190722. PubMed ID: 31964274
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
5. Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2.
Yi GZ; Huang G; Guo M; Zhang X; Wang H; Deng S; Li Y; Xiang W; Chen Z; Pan J; Li Z; Yu L; Lei B; Liu Y; Qi S
Brain; 2019 Aug; 142(8):2352-2366. PubMed ID: 31347685
[TBL] [Abstract][Full Text] [Related]
6. The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
Annovazzi L; Caldera V; Mellai M; Riganti C; Battaglia L; Chirio D; Melcarne A; Schiffer D
Int J Oncol; 2015; 46(6):2299-308. PubMed ID: 25892134
[TBL] [Abstract][Full Text] [Related]
7. GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
Ma J; Wang Z; Chen CC; Li M
Oncotarget; 2023 May; 14():483-484. PubMed ID: 37204260
[No Abstract] [Full Text] [Related]
8. Mechanism-based design of agents that selectively target drug-resistant glioma.
Lin K; Gueble SE; Sundaram RK; Huseman ED; Bindra RS; Herzon SB
Science; 2022 Jul; 377(6605):502-511. PubMed ID: 35901163
[TBL] [Abstract][Full Text] [Related]
9. Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.
Chalmers AJ
Anticancer Agents Med Chem; 2010 Sep; 10(7):520-33. PubMed ID: 20879987
[TBL] [Abstract][Full Text] [Related]
10. DNA repair mechanisms and their clinical impact in glioblastoma.
Erasimus H; Gobin M; Niclou S; Van Dyck E
Mutat Res Rev Mutat Res; 2016; 769():19-35. PubMed ID: 27543314
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
12. Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.
Head RJ; Fay MF; Cosgrove L; Y C Fung K; Rundle-Thiele D; Martin JH
Cancer Biol Ther; 2017 Dec; 18(12):917-926. PubMed ID: 29020502
[TBL] [Abstract][Full Text] [Related]
13. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
14. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
[TBL] [Abstract][Full Text] [Related]
15. Kinesin Family Member C1 Increases Temozolomide Resistance of Glioblastoma Through Promoting DNA Damage Repair.
Wu J; Wang X; Yuan X; Shan Q; Wang Z; Wu Y; Xie J
Cell Transplant; 2021; 30():963689721991466. PubMed ID: 33588605
[TBL] [Abstract][Full Text] [Related]
16. GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
Xu H; Jin J; Chen Y; Wu G; Zhu H; Wang Q; Wang J; Li S; Grigore FN; Ma J; Chen CC; Lan Q; Li M
Oncogene; 2022 Jul; 41(31):3876-3885. PubMed ID: 35780181
[TBL] [Abstract][Full Text] [Related]
17. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Ferri A; Stagni V; Barilà D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment.
Lozinski M; Bowden NA; Graves MC; Fay M; Day BW; Stringer BW; Tooney PA
Cells; 2022 Apr; 11(7):. PubMed ID: 35406779
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma vs temozolomide: can the red queen race be won?
Arora A; Somasundaram K
Cancer Biol Ther; 2019; 20(8):1083-1090. PubMed ID: 31068075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
